Genentech, Inc.

Meredith C Hazen

Dhaya Seshasayee

Jo-Anne Hongo

Yan Wu

Wei-Ching Liang

Philip E Hass

Menno Van Lookeren Campagne

Gerald R Nakamura

Wenwu Zhai

Nancy Chiang

Yi-Chun Hsiao

Jack Bevers, Iii

Joseph R Arron

Heleen Scheerens

Yanan Zheng

Rajita Khosla

Hongkang Xi

Wendy Putnam

Richard W Erickson

Michelle Freemer

Guiquan Jia

John G Matthews

Andrew G Polson

Allen J Ebens

Jane Louise Grogan

Teemu T Junttila

Patrick Lupardus

Ji Li

Robert J Johnston

Mahesh Yadav

Jennifer W Johnston

Victoria Smith

Jagath Reddy Junutula

Robert A Lazarus

Isidro Hotzel

Shang-Fan Yu

Steven Elliot Kauder

Zhonghua Lin

Sunil Bhakta

Yonglei Shang

Susanna Y Stinson

Jackson G Egen

Lydia Santell

The instant technology generally relates to improved methods for producing antibodies, antibody libraries, hybridomas, hybridoma libraries, etc. For example, these methods increase the number of antigen-specific B cells produced, increase the number of hybridomas, and/or increase the number of monoclonal antibodies that can be made in a given production cycle.

Developing an efficient hybridoma platform for therapeutic antibody discovery

The invention provides interleukin-33 (IL-33) antibodies and methods of using the same.

Anti-interleukin-33 antibodies and uses thereof

The invention provides anti-FcRH5 antibodies and immunoconjugates and methods of using the same.

Anti-FCRH5 antibodies

Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.

Method of treating asthma using an IL-13 antibody

Anti-FcRH5 antibodies

The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Anti-TIGIT antibodies and methods of use

Anti-tigit antibodies and methods of use

This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.

Method of reducing blood glucose by administering RON agonists

Diagnosis and treatments relating to TH2 inhibition

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.

Compositions and methods for the diagnosis and treatment of tumor

NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.

NLRR-1 antagonists and uses thereof

Growing community of inventors

Belmont, CA, United States of America

Meredith C Hazen